Share on

Global Atopic Dermatitis Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Treatment Type (Drug Treatment and Radiation Treatment), Route Of Administration (Topical and Oral), Distribution Channel & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 5169
Pages: 175
Formats: report pdf report excel report power bi report ppt

Atopic Dermatitis Market Size (2022 to 2027)

As per our report, the global atopic dermatitis market size was valued at USD 11.77 billion in 2022. It is expected to grow at a CAGR of 13.13% and be worth USD 21.80 billion by 2027. Therefore, the market is expected to progress steadily through the forecast period.

Atopic Dermatitis is an inflammatory skin disease, and its severity varies from patient to patient. It usually begins in childhood and is mainly confined to the flexural surfaces of the body. It is highly prevalent and is more commonly known as eczema. Itching, redness of the skin, cracking, weeping, etc., are symptoms, and it is a long-term disease. Low humidity, cold weather, and seasonal allergies are the common causes of it, and the pattern of the disease and its severity determine the kind of treatment it ought to receive.

Some of the key findings of the report:

  • Based on the treatment type, the drug treatment segment dominated the market in 2021.
  • Based on the route of administration, the topical segment accounted for the major share of the atopic dermatitis market in 2021.
  • Based on the distribution channel, the hospital segment had the leading share of the market in 2021.
  • The North American region led the market and was valued at USD 3.56 billion in 2021.
  • The European region is anticipated to be worth USD 6.31 billion by 2027.
  • The Asia-Pacific region is expected to grow at a CAGR of 15.18% from 2022 to 2027.

MARKET DRIVERS:

YOY growth in the incidence of atopic dermatitis, the launch of biologics & small molecules, premium-priced drugs substituting generic first line and second-line therapeutics, and improved diagnostics are propelling the growth of the global atopic dermatitis market.

Growing skin allergies and chronic disorders are expected to accelerate the market’s growth rate. Atopic dermatitis disease severity ranges from patient to patient, and the treatment procedures involve the severity degree. Escalating expenditure on healthcare and the growing popularity of these treatment procedures through digital advertisements accelerates the global atopic dermatitis market growth. Additionally, a growing number of initiatives from various governments to improve the infrastructure of hospitals and clinics with the latest equipment are expected to expand the growth scope for the global atopic dermatitis market. Furthermore, an increasing number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income in both developed and developing countries are further expected to accelerate the market's growth rate. Besides, the emergence of the latest technologies in the medical sector and the introduction of innovative procedures magnify this market's growth.

Growing incidence of atopic dermatitis condition in children is expected to boost the atopic dermatitis market forward.

Most people have sleep disturbances problems suffering from atopic dermatitis in 67% of children. Poor sleep may affect growth in children. Children with AD will also suffer from a condition like food allergy, allergic rhinitis, and asthma. Usually, AD starts in early childhood and development into other allergic disorders later in life. This drives the market forward.

Increasing awareness of atopic dermatitis drives the market forward.

Increasing awareness of AD people by using herbal medicine, natural ointment, and ultraviolet therapy boosts the market. Medical institutions are providing education about AD and its primary treatment at home. Much research is going to find fast relief for the disease. All these factors drive the market forward.

MARKET RESTRAINTS:

Rising complications and side effects after the treatment procedure in some people hinder the demand of the global atopic dermatitis market. In addition, oral medicine can have some severe side effects when it has been taken for a more extended period. Furthermore, the shortage of skilled people in hospitals and clinics and fluctuations in economic strategies negatively impact the growth rate of the atopic dermatitis market. In addition, less availability of necessary equipment in rural areas remains a challenging factor for the market players. Also, the high cost of the treatment procedures due to advanced features is declining the growth rate of this market.

Impact of COVID-19 on the global atopic dermatitis market:

The sudden outburst of the new coronavirus (COVID-19) was caused by the severe acute respiratory syndrome SARS- CoV-2 reagent. The pandemic crisis has affected every industry in terms of profit or production. Atopic dermatitis doesn't affect critical markers' regularity in patients hospitalized with coronavirus. Adults with atopic diseases are at a significant risk of lower respiratory tract infections (LRTIs) and Upper respiratory tract infections (URTIs) than those without atopic diseases. Patients infected with coronavirus didn't face any difficulties during their infection course.

Moreover, patients with atopic dermatitis are said to have an efficient and safe therapy with dupilumab. During the COVID-19 pandemic period, the market of tele dermatology has increased due to a drop in frequent clinical visits because of sanitary restrictions. Most patients with Atopic Dermatitis (AD) continue their generalized treatment, and patients should not stop their oral and biological therapy or other existing treatments without consulting their physicians. As per the National Eczema Association, the coronavirus (COVID-19) pandemic crisis doesn't increase the threat of life-threatening issues in people with eczema. On the other hand, people with atopic dermatitis have higher incidences of anxiety and depression, and patients are found to account for increased occurrences in the emergency department. All these factors are expected to accelerate the growth rate of the global atopic dermatitis market during the forecast period.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2021 to 2027

Base Year

2021

Forecast Period

2022 to 2027

Segments Covered

By Treatment Type, Route of Administration, Distribution channel, and Region.

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis; DROC, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

 

This market research report on the global atopic dermatitis market has been segmented and sub-segmented into the following categories.

Atopic Dermatitis Market - By Treatment Type:

  • Drug Treatment
  • Radiation Treatment

Based on treatment type, the drug treatment segment held the largest market share in 2021 owing to the rise in the prevalence of early-diagnosis diseases. In addition, investments in research and development institutes to improve healthcare centers' services bolstered the market's growth rate.

Radiation Treatment is another segment that drives the market forward—increasing people taking radiation therapy for dermatitis-based diseases to increase the quality of life. For example, phototherapy is used for atopic dermatitis with ultraviolet radiation. This treatment involves exposing the skin to ultraviolet light to help reduce itching and inflammation. The treatment is taken in a particular place with fluorescent lamps that emit light of a specific wavelength. These lights treat individual parts of your body, such as your head, hands, or feet.

Atopic Dermatitis Market - By Route of Administration:

  • Topical
  • Oral

Based on the administration route, the topical segment leads with a dominant market share, whereas the oral segment will have the highest CAGR in the coming years. Support from public and private organizations over managing all the operations in the hospitals and clinics only to provide effective treatment procedures is expanding the market share.

The oral medication segment also drives the market forward. If the skin disease is in an advanced stage, most healthcare provider gives oral pills to help control the symptoms. In addition, at-home therapies use this oral medication for moderate to severe atopic dermatitis.

Atopic Dermatitis Market - By Distribution Channel:

  • Hospital pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Based on the distribution channel, the hospital pharmacies segment is ruling with the highest market share due to the increasing scale of hospitals and clinics worldwide—the growing flow of patients to hospitals fuels the demand for the global Atopic Dermatitis Market.

Atopic Dermatitis Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The North American atopic dermatitis market had a significant share of the global market in 2021 and is anticipated to register the lead during the forecast period. New product launches, early treatment adoption, and lifestyle changes are the reasons behind it. According to recent studies, forty percent of people in America are suffering from moderate to severe atopic dermatitis diseases and emotional burden in addition to pain, physical discomfort, and sleep disturbance for 16.8 million people in the U.S. It is a skin disease that results in rashes and patches of itchy skin, mainly around the neck, face, and eyes. In addition, 18% of Canadians suffer from atopic dermatitis (AD). It is a visible skin disease that impacts the quality of life through depression, anxiety, and psychosocial issues. Health Canada has approved CIBINQO (abrocitinib) for treating atopic dermatitis patients aged 12 years and older. However, many Canadian AD patients want to connect with peers for further support and need mental health resources.

Globally, the European atopic dermatitis market is predicted to be the second-largest regional market during the forecast period. Heavy investment in R&D activities in this region is the cause of the observable trend mentioned above. As a result, European countries like Spain and the United Kingdom are expected to showcase promising growth from 2020 to 2025. Nearly 5 percent of German adults suffer from atopic dermatitis (AD). German people are using many treatments for these diseases. In addition to UV therapy and proactive topical therapy, the European guideline for treating AD include reactive topical therapy for mild AD or temporary eczema and proactive topical therapy for moderate AD. German people have so many guidelines for treatment. Systemic drugs and phototherapy are used for skin diseases. Unfortunately, German patients still suffer from a high burden of disease and a low quality of life, indicating insufficient medication. 

The Asia Pacific atopic dermatitis market is predicted to be the fastest-growing global atopic dermatitis treatment market in the abovementioned forecast. Japan is forecasted to register the highest CAGR during the same period. This region extension can be attributed to victims' significant unmet clinical needs, increasing spending on healthcare, and adequate treatment availability. Indian Dermatology Expert Board Members have provided several guidelines for atopic dermatitis. In India, advanced drugs and treatments are provided for PD diseases. Several hospitals are adopting treatment for this disease as more people suffer from AD. This mainly occurred due to climate changes in India. The incidence of AD in China has rapidly increased during the past ten years. Most people aged 10-30 years suffer from these diseases requiring treatment. Chinese Society of Dermatology Immunology Group developed guidelines for the Diagnosis and Treatment of Atopic Dermatitis in China. Rapid advances in diagnosing and treating AD in the past five years globally and in China will drive the market forward. AD is the second most skin disease in Japan. In Japan, most children suffer from this disease. In 2021, the Japanese Ministry of Health, Labour, and Welfare (MHLW) approved the CIBINQO drug, which is oral, for the treatment of moderate to severe atopic dermatitis (AD) in adults. Along with this, Moizerto® Ointment is also approved in Japan and is manufactured by Otsuka Pharmaceutical Co., Ltd. for people suffering from atopic dermatitis in 2021.

The Latin American atopic dermatitis market is expected to grow significantly in the next five years due to a rapidly growing population, changing lifestyles, and a paradigm shift towards western lifestyles; increasing R&D and a large target patient pool are attributable to the observable trend mentioned above. As per the reports, 8 percent of adults suffer from AD in Brazil. The causes of PD in Latin American countries are tropical, temperate, and cold temperatures, humidity, pollution, ultraviolet ray exposure, average time spent indoors, and allergen exposure.

The MEA atopic dermatitis market is anticipated to undergo sluggish growth in the abovementioned forecast period.

KEY MARKET PARTICIPANTS:

Some of the notable companies profiled in the global atopic dermatitis market in this report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., Anacor Pharmaceuticals, Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer Inc.

RECENT MARKET DEVELOPMENTS:

  • In 2022, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration (FDA) approved Dupixent for children aged six months to 5 years for people suffering from atopic dermatitis.
  • In 2022, Evelo Biosciences, Inc. developed SYNTAX medicines used as orally delivered treatments for inflammatory diseases such as moderate and severe atopic dermatitis.
  • AbbVie Inc and Pfizer Inc (PFE.N) have manufactured drugs to treat atopic dermatitis, which was approved by the U.S. Food and Drug Administration in 2022. This drug was treated for a patient who was not responding to previous treatments.
  • Crisborole, a non-steroidal topical anti-inflammatory, is developed by Anacor Pharmaceuticals and has significant use for various skin diseases in adults.
  • Dupilumab is another drug approved to treat severe atopic dermatitis treatment.

Please wait. . . . Your request is being processed

FAQ's

How big is the atopic dermatitis market?

As per our research report, the global atopic dermatitis market size was valued at USD 11.77 billion in 2022 and is estimated to grow by USD 21.8 billion by 2027.

Which segment by treatment type held the dominant share in the atopic dermatitis market in 2021?

Based on the treatment type, the drug type accounted for the major share of the global atopic dermatitis market in 2021.

Which geographical region led the atopic dermatitis market in 2021?

Among all the regions, the North American region was the leader in the global atopic dermatitis market in 2021.

Who are key players in the global atopic dermatitis market?

Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., Sanofi S.A., Anacor Pharmaceuticals, Inc.., Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., Novartis International AG, and Pfizer Inc. are a few of the noteworthy companies in the global atopic dermatitis market.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample